Breaking News

Horizon Expands Commercial Division

Adds six executives, moves into a 20,000-sq.-ft. facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Discovery has added six individuals to its commercial division, including sales, marketing and business development covering the U.S., Europe and the Far East. Additionally, the company has expanded its facilities at the IQ Cambridge Research Park in Cambridge, UK.
 
Among the appointments, Kam Dhaliwal has been named director of business development, responsible for managing the company’s business development efforts. Mr. Dhaliwal joins the company from Evotec AG, where he was vice president of business development, responsible for growing the company’s business in Belgium, the Netherlands, Scandinavia, Spain and the UK within the biotechnology and pharmaceutical sectors, as well as academic institutes.
 
In the last year Horizon has grown from 25 employees to more than 65 and has expanded its UK-based premises, moving into a purpose-fitted 20,000-sq.-ft. facility. The Cambridge facility will house the company’s precision genome editing, reagents, discovery services and diagnostics divisions and will allow space for more than 130 employees.
 
Dr. Darrin Disley, executive chairman of Horizon, said, “Horizon continues to grow rapidly based on a high-level of customer demand for our expanding range of products and services. Our leadership position in precision human genome editing using rAAV targeting vectors that enable the insertion, deletion or substitution of any DNA sequence into any target locus in any cell line is the driving force of this growth. Our global network of customers, collaborators and centers of excellence will be better served by this expansion and we look forward to the year ahead with great optimism.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters